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Buffer transport in peritoneal dialysis. The success of peritoneal
dialysis as a robust modality of renal replacement therapy has
invited a quest for ameliorations in its underlying technology
aimed at enhancing patient satisfaction and preserving the cen-
tral instrument of the therapy, namely the peritoneal membrane.
The health and longevity of the membrane have motivated and
continue to drive a series of iterative innovations in the compo-
sition, methods of production, and delivery of dialysis solutions.
It is the purpose of this article to review aspects of these innova-
tions pertaining to buffer composition in dialysis solutions and
the peritoneal mechanisms of buffer transport.
BUFFERS SYSTEMS IN PERITONEAL DIALYSIS
The buffer composition of peritoneal dialysis (PD) so-
lutions can be divided broadly into three categories: non-
bicarbonate buffers, bicarbonate, and a complementary
mixture of bicarbonate and nonbicarbonate. The non-
bicarbonate buffers are predominantly components of
the normal glycolytic pathway (Fig. 1); acetate, lactate,
and pyruvate, and as such are naturally occurring com-
pounds with established metabolic fate. Acetate is only
of historic interest as it has been long abandoned, not
because of any major systemic consequence, but rather
because it has been implicated in inducing injury to the
peritoneal membrane, leading in some cases to encap-
sulating peritoneal sclerosis (EPS) [1]. The pathogenic
role of acetate, however, was not definitely established,
as not all formulations of acetate-based solutions were
associated with the membrane transport changes. Pyru-
vate has not been used in clinically applicable solutions
but its advantages have become the subject of recent in-
terest and publications [2–4]. Lactate remains the pre-
dominant nonbicarbonate buffer used either solely as the
unique source of alkali or as a complementary source in
solutions using bicarbonate-lactate buffer systems. Sev-
eral characteristics of lactate have sustained its popular-
ity as a source of alkali replenishment in patients on PD,
it being a natural component of the glycolytic pathway
with a clear and well delineated metabolic fate, its sta-
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bility and ease of use in the formulation of large vol-
ume parenteral solutions, and its long history of safety
and success in both intravenous (lactated Ringer’s so-
lution) and intraperitoneal preparations. In a separate
paper in this supplement, we have reviewed the clinical
success of lactate in correcting the metabolic acidosis of
uremia.
Until recently, lactate was thought of as a dead-end
metabolic product formed as a result of an imbalance
between the production of pyruvate through glycolysis
and the capacity to oxidize pyruvate, the latter being di-
minished during anaerobic metabolism. The accumulat-
ing pyruvate under these conditions was thought to be
shunted into a cul-de-sac as lactate. Lactate is actually an
intermediate and not a metabolic “dead end” product.
Even in fully oxygenated muscle tissue, as much as 50%
of the glucose metabolized is converted to lactate.
Lactate is produced exclusively by glycolysis and is
removed either by recycling the carbons to glucose or
by complete oxidation to H2O and CO2. The first step
in the utilization of lactate is the reoxidation of lac-
tate to pyruvate (i.e., driving the reaction pyruvate +
NADH←→NAD+ + lactate against its equilibrium).
In the nonexercising individual, the liver is responsi-
ble for a large fraction of the daily lactate uptake (about
60%). The periportal hepatocytes convert lactate to ei-
ther glucose or glycogen at all times (in the periportal
hepatocytes, flux is always from pyruvate to glucose-6-
phosphate (G6P) and never in the opposite direction)
(Fig. 1). In addition, the periportal cells take up lactate as
energy sources when fatty acids (their preferred energy
source) are not available. This is the case after the inges-
tion of a fat-free meal. Under these conditions, lactate
is the only fuel available to the periportal hepatocytes,
and lactate removal from the blood is at its highest in
the nonexercising individual. (Nevertheless, the plasma
lactate concentration does not decrease under these con-
ditions because the increase in lactate uptake is compen-
sated by the simultaneous increase in lactate production
by the perivenous liver cells.)
It is estimated that in the nonexercising individual
about 40% of the daily output of lactate is removed by
mitochondria-rich cells (e.g., aerobic muscle fibers that
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Fig. 1. Schematic representation of the metabolism of lactate, pyru-
vate, and acetate in liver periportal cells. G6P, glucose-6-phosphate.
are permanently active in maintaining posture and the
epithelium of the proximal kidney tubules). These cells
have a high rate of ATP hydrolysis and are well equipped
to use lactate as energy supply. They take up lactate
from the blood because they have an active shuttle sys-
tem which keeps the nicotinamide adenine dinucleotide
(NAD) oxidized; this pulls the equilibrium between lac-
tate and pyruvate toward pyruvate, which then is oxidized
to CO2 + H2O.
The metabolism of lactate occurs in a variety of tis-
sues, even ones previously considered as lactate pro-
ducers (such as muscle), and the transport of lactate is
currently known to occur via monocarboxylate trans-
porters, which also transport pyruvate. The load of lactate
absorbed in PD is greatly inferior to the rate of production
of lactic acid in normal humans (15 to 30 mEq/kg/day),
and no elevation in serum lactate has been reported in
patients on PD.
BUFFER TRANSPORT IN PERITONEAL
DIALYSIS
The kinetics of buffer transport in peritoneal dialy-
sis have been evaluated in a limited number of stud-
ies and the findings reflect the particular buffer system
used. The following discussion will review these data
under the heading of whether the buffer system used
was based on a single source of alkali or mixed sources.
In lactate-based solutions and in solutions with comple-
mentary bicarbonate-lactate composite buffer systems,
no changes occur in blood acid-base parameters during
a single dwell in patients under steady-state conditions
with chronic therapy (Table 1).
Single-buffer system
Three single-buffer system solutions have been used
clinically: acetate, lactate, and bicarbonate. As indicated
above, acetate is only of historical interest as it is no
longer in use because of its toxicity at the level of the peri-
toneal membrane [5, 6]. Furthermore, elevations in blood
acetate levels are observed during acetate-buffer dialy-
sis, whereas lactate levels remain normal [7]. The higher
rate of conversion of acetate to bicarbonate compared to
lactate also resulted in plasma bicarbonate levels above
normal [7]. Unlike hemodialysis, where there is a uni-
directional transfer of alkali from dialysate to blood,
in lactate-based single-buffer solutions, a bidirectional
transport of alkali source occurs based on the composi-
tion of the solution. Because lactate-based single-buffer
solutions are by definition devoid of bicarbonate, the lat-
ter will diffuse from the blood side to the dialysate down
its concentration gradient, resulting in a loss of this al-
kali. The profile of this diffusion of bicarbonate into the
dialysate is illustrated in Figure 2. There is a rapid ini-
tial diffusion of bicarbonate into the dialysis solution fol-
lowed by a progressive increase so that by four hours into
the dwell the bicarbonate concentration in the dialysate
approaches that in the blood. The final dialysate bicar-
bonate, as well as the rate of change at 60 and 240 min-
utes into the dwell, correlates with the levels of blood
bicarbonate at the beginning of the dwell (r = 0.79, P <
0.0001 for the correlation of final dialysate bicarbonate
with blood bicarbonate) (Fig. 3). This implies that bicar-
bonate loss is “regulated” by the prevailing level of sys-
temic bicarbonate and lower losses would be observed in
acidotic patients, as has been found by Hernandez-Jaras
et al [8]. The progressive rise in bicarbonate is associated
with a parallel rise in dialysate pCO2 (Fig. 4). The changes
in the two components of this buffer system are reflected
in the changes in dialysate pH, which rises rapidly at the
beginning of the dwell but does not reach blood pH lev-
els until 120 minutes after instillation into the peritoneal
cavity (Fig. 5).
While bicarbonate is diffusing from blood to dialysate,
lactate diffuses from dialysate to blood down its own con-
centration gradient [8, 9]. This diffusion is rapid during
the first hour of the dwell and continues at a slower rate
subsequently (Fig. 6), a profile of transport similar to
that of glucose, while the rise of bicarbonate levels in
the dialysate closely resembles the changes in creatinine
[9], although the equilibration rate is slightly faster for bi-
carbonate than for creatinine. These similarities are more
than apparent; they imply that the absorption of lactate
and the loss of bicarbonate follow the kinetics of glucose
and creatinine and, hence, during a standard continuous
ambulatory peritoneal dialysis (CAPD) dwell will dis-
tribute according to standard peritoneal transport classi-
fications. Indeed, Hernandez-Jaras et al [8] have shown
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Table 1. Blood measures during a single dwell with a bicarbonate/lactate solution (B/L) or a traditional lactate solution (TL)
pH pCO2 HCO3
B/L TL B/L TL B/L TL
Before 7.36 ± .02 7.38 ± .02 6.06 ± .19 6.18 ± .24 25.13 ± .87 26.86 ± 1.18
15 min 7.35 ± .01 7.37 ± .02 6.45 ± .20 6.48 ± .27 26.15 ± 1.14 27.35 ± 1.55
60 min 7.35 ± .01 7.37 ± .02 6.18 ± .18 6.28 ± .35 25.02 ± .92 26.78 ± 1.48
120 min 7.37 ± .01 7.37 ± .02 6.17 ± .26 5.69 ± .44 26.00 ± .84 24.31 ± 2.03
240 min 7.38 ± .02 7.38 ± .02 6.20 ± .22 6.13 ± .30 26.80 ± .65 26.71 ± 1.18
Data from Heimburger et al: Peritoneal transport with lactate 40 mmol/L (L) vs. bicarbonate/lactate 25/15 mmol/L (BL) dialysis fluids. J Am Soc Nephrol 9:192A, 1998.
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Fig. 2. Temporal profile of dialysate bicarbonate with two dialysis solu-
tions: traditional lactate solution () and a solution with a mixed-buffer
preparation (bicarbonate/lactate) (gray squares). The study was per-
formed in seven subjects who received both preparations in random
order. Data from Heimburger et al: Peritoneal transport with lactate
40 mmol/L (L) vs. bicarbonate/lactate 25/15 mmol/L (BL) dialysis fluids.
J Am Soc Nephrol 9:192A, 1998.
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Fig. 3. Correlation between blood bicarbonate level and end-of-dwell
dialysate bicarbonate concentration with the use of lactate-based dial-
ysis solution. Data from Heimburger et al: Peritoneal transport with
lactate 40 mmol/L (L) vs. bicarbonate/lactate 25/15 mmol/L (BL) dial-
ysis fluids. J Am Soc Nephrol 9:192A, 1998.
that lactate gain was higher in high and high-average pa-
tients than in low and low-average patients, both during
a single dwell (53.9 vs. 48.8 mEq/4 hours, P < 0.01) as
well as during a 24-hour therapy (228.0 vs. 209.9 mEq/
24 hours, P < 0.05). Similarly, they observed that bicar-
bonate loss also followed standard peritoneal kinetics and
was higher in high and high-average patients than in low
and low-average patients, both during a single dwell (48.6
vs. 43.2 mEq/4 hours, P < 0.05) as well as during a 24-hour
therapy (187.2 vs. 177.9 mEq/24 hours) [8]. This depen-
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Fig. 4. Temporal profile of dialysate pCO2 with two dialysis solutions:
traditional lactate solution () and a solution with a mixed-buffer
preparation (bicarbonate/lactate) (gray squares). The study was per-
formed in seven subjects who received both preparations in random
order. Data from Heimburger et al: Peritoneal transport with lactate
40 mmol/L (L) vs. bicarbonate/lactate 25/15 mmol/L (BL) dialysis fluids.
J Am Soc Nephrol 9:192A, 1998.
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Fig. 5. Temporal profile of dialysate pH with two dialysis solutions: tra-
ditional lactate solution () and a solution with a mixed-buffer prepara-
tion (bicarbonate/lactate) (gray squares). The study was performed in
seven subjects who received both preparations in random order. Data
from Heimburger et al: Peritoneal transport with lactate 40 mmol/L
(L) vs. bicarbonate/lactate 25/15 mmol/L (BL) dialysis fluids. J Am Soc
Nephrol 9:192A, 1998.
dence of buffer kinetics in CAPD on peritoneal transport
profile is consistent with the findings reported by us in a
separate contribution to this supplement.
The above findings imply that with a single lactate-
based buffer system, a dual alkali exchange takes place
characterized by bicarbonate loss and lactate gain [8–
12] (Fig. 7). Bicarbonate loss seems to be regulated
by a dual system: plasma bicarbonate and peritoneal
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Fig. 6. Temporal profile of dialysate bicarbonate and lactate with tra-
ditional lactate solution. Redrawn from reference [9].
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Fig. 7. Daily balance of alkali (lactate gain and bicarbonate loss) dur-
ing continuous ambulatory peritoneal dialysis (CAPD) treatment with
traditional lactate solution. Panel (A) from reference [11], panel (B)
from reference [8].
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Fig. 8. Effect of an increase in total alkali content in lactate-based solu-
tions on plasma bicarbonate in patients on continuous ambulatory peri-
toneal dialysis (CAPD). Black circles indicate solutions of 35 mmol/L
lactate; gray squares indicate solutions of 40 mmol/L lactate. Redrawn
from reference [14].
transport characteristics [8]. Once the plasma and
dialysate bicarbonate have equilibrated, the net bicar-
bonate loss will also be directly proportional to the
drained volume due to mass balance. The higher the
plasma bicarbonate and the higher the transport status,
the larger the bicarbonate loss. The dependence of bi-
carbonate loss on systemic bicarbonate can be viewed as
a “regulatory” component; patients with low bicarbon-
ate lose less, and if systemic alkali levels are elevated,
then bicarbonate losses are increased. This “regulatory”
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Fig. 9. Profile of the levels of pCO2 prevailing in dialysis solutions of
different concentrations of bicarbonate at various pH levels. The val-
ues for solutions with complementary bicarbonate/lactate buffer with
bicarbonate concentration of 25 are indicated in the gray circle. The
open circle encompasses the values for pure bicarbonate solutions of
various concentrations.
component, however, has no physiologic anchor, as the
dialysate is bicarbonate-free at the beginning of the dwell.
This may explain why early in the history of CAPD, aci-
dosis was observed when lower levels of lactate were used
(35 mmol/L) [13], and the amelioration of that condition
with the introduction of higher levels of lactate (Fig. 8)
[14,15]. Lactate gain is regulated only by peritoneal trans-
port characteristics as plasma lactate does not change
during a dwell due to the rapid metabolic sink for the
molecule [8]. The overall effects of these two processes
on alkali balance in a 24-hour period are illustrated in
Figure 7 from two studies [8, 11]. In both papers [8, 11],
lactate gain exceeds bicarbonate loss so the net effect
is alkali gain, which accounts for the correction of the
metabolic acidosis in these patients.
In a single bicarbonate-based buffer system, the above
kinetics do not apply. The diffusion of bicarbonate is uni-
directional (dialysate to blood) and would be subject to
the concentration gradient, but since the concentration of
bicarbonate used in most commercial preparations is al-
ways higher than blood [16–20], there is an obligatory gain
of bicarbonate irrespective of the acid-base status of the
patient. This bicarbonate gain is likely regulated by both
systemic bicarbonate levels [21, 22], as well as peritoneal
transport characteristics. At low systemic bicarbonate, al-
kali gain is higher, but when systemic bicarbonate is high,
there is no opportunity for alkali loss. Further, the formu-
lation of a high bicarbonate single-buffer system requires
the presence of high levels of pCO2 for the provision of
a preparation at physiologic pH (Fig. 9).
Complementary buffer system
Currently, only one complementary mixed-buffer sys-
tem with two formulations is available for clinical use:
a combination of bicarbonate at a physiologic level of
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Fig. 10. Overall profile of the changes in
dialysate composition during a standard
continuous ambulatory peritoneal dialy-
sis (CAPD) dwell with traditional lactate
solution.
Fig. 11. Overall profile of the changes in
dialysate composition during a standard
continuous ambulatory peritoneal dialy-
sis (CAPD) dwell with bicarbonate/lactate
solution.
25 mEq/L with one of two concentrations of lactate (10
or 15 mmol/L) [20, 23–27]. The presence of a physio-
logic concentration of bicarbonate provides a physiologic
adjustor to the process of bicarbonate transport across
the peritoneal membrane. At systemic levels of bicar-
bonate lower than normal physiologic, bicarbonate will
diffuse from the dialysate to blood. When prevailing
systemic bicarbonate levels are higher than normal, bi-
carbonate will diffuse from blood to dialysate. The phys-
iologic level of bicarbonate in the dialysate solution
anchors the process. As illustrated in Figure 2, dialysate
bicarbonate remains stable throughout the dwell, and
so do dialysate pCO2 (Fig. 4) and dialysate pH (Fig. 5),
as all three parameters have been formulated at normal
physiologic levels. With this mixed-buffer system, there
is no window of intraperitoneal acidosis and no unregu-
lated transport of bicarbonate. The physiologic level of
bicarbonate, however, continues to allow for some bi-
carbonate loss in case of systemic alkali excess. Lactate is
provided at two concentrations to allow for titration of al-
kali dose delivery, and the kinetics of lactate in this system
are similar to its use in a single system except for the lower
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concentration. With this mixed-buffer system, two com-
plementary processes allow regulation of alkali balance,
a physiologic level of bicarbonate and pCO2 and a low
level of lactate as an additional buffer source. In patients
with systemic alkali levels below physiologic, alkali reple-
tion is achieved by both bicarbonate and lactate gain. In
patients with systemic alkali levels above physiologic, bi-
carbonate loss to normal physiologic levels is feasible, and
the level of lactate can be chosen based on metabolic re-
quirements. The clinical success of this system in CAPD
and APD is detailed separately in two contributions in
this supplement.
CONCLUSION
Several buffer systems are available for clinical use in
peritoneal dialysis. Single-buffer systems rely either on
the provision of bicarbonate or a bicarbonate metabolic
precursor (lactate, puyruvate, acetate). These single sys-
tems are hampered either by lack of regulatory flexibility
and high levels of pCO2 (bicarbonate) (Fig. 9), or partially
unregulated bicarbonate loss (lactate, pyruvate) (Fig. 10).
Mixed-buffer systems at variable total buffer mass are
gaining wide clinical use and offer the advantages of ad-
justment to patient metabolic requirement, as well as
allowing buffer balance to operate under regulation of
physiologic bicarbonate/pCO2 levels (Fig. 11).
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